Janet C Lindsey
Overview
Explore the profile of Janet C Lindsey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
2706
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hill R, Kuijper S, Lindsey J, Petrie K, Schwalbe E, Barker K, et al.
Cancer Cell
. 2014 Dec;
27(1):72-84.
PMID: 25533335
We undertook a comprehensive clinical and biological investigation of serial medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family amplifications and P53 pathway defects commonly emerged at relapse, and...
12.
Shih D, Northcott P, Remke M, Korshunov A, Ramaswamy V, Kool M, et al.
J Clin Oncol
. 2014 Feb;
32(9):886-96.
PMID: 24493713
Purpose: Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection,...
13.
Lindsey J, Schwalbe E, Potluri S, Bailey S, Williamson D, Clifford S
Acta Neuropathol
. 2013 Dec;
127(2):307-9.
PMID: 24337442
No abstract available.
14.
Schwalbe E, Hayden J, Rogers H, Miller S, Lindsey J, Hill R, et al.
Acta Neuropathol
. 2013 Nov;
126(6):943-6.
PMID: 24212602
No abstract available.
15.
Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih D, Martin D, et al.
J Clin Oncol
. 2013 Jul;
31(23):2927-35.
PMID: 23835706
Purpose: Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer conflicting conclusions. We resolve this issue through the inclusion of molecular subgroup profiles. Patients And Methods: We determined...
16.
Schwalbe E, Williamson D, Lindsey J, Hamilton D, Ryan S, Megahed H, et al.
Acta Neuropathol
. 2013 Jan;
125(3):359-71.
PMID: 23291781
Molecular subclassification is rapidly informing the clinical management of medulloblastoma. However, the disease remains associated with poor outcomes and therapy-associated late effects, and the majority of patients are not characterized...
17.
Northcott P, Shih D, Peacock J, Garzia L, Morrissy A, Zichner T, et al.
Nature
. 2012 Jul;
488(7409):49-56.
PMID: 22832581
Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, with at...
18.
Levesley J, Lusher M, Lindsey J, Clifford S, Grundy R, Coyle B
Neuro Oncol
. 2011 Sep;
13(12):1265-76.
PMID: 21880625
The RASSF1A tumor suppressor is potentially the most important candidate gene identified in medulloblastoma to date, being epigenetically silenced in >79% of primary tumors. However, its functional role has not...
19.
Lindsey J, Hill R, Megahed H, Lusher M, Schwalbe E, Cole M, et al.
J Clin Oncol
. 2011 Mar;
29(12):e344-6.
PMID: 21357788
No abstract available.
20.
Schwalbe E, Lindsey J, Straughton D, Hogg T, Cole M, Megahed H, et al.
Clin Cancer Res
. 2011 Feb;
17(7):1883-94.
PMID: 21325292
Purpose: Microarray studies indicate medulloblastoma comprises distinct molecular disease subgroups, which offer potential for improved clinical management. Experimental Design: Minimal mRNA expression signatures diagnostic for the Wnt/Wingless (WNT) and Sonic...